作者
HaiFang Yin, Corinne Betts, Amer F Saleh, Gabriela D Ivanova, Hyunil Lee, Yiqi Seow, Dalsoo Kim, Michael J Gait, Matthew JA Wood
发表日期
2010/4/1
期刊
Molecular Therapy
卷号
18
期号
4
页码范围
819-827
出版商
Elsevier
简介
Antisense oligonucleotides (AOs) have the capacity to alter the processing of pre-mRNA transcripts in order to correct the function of aberrant disease-related genes. Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle degenerative disease that arises from mutations in the DMD gene leading to an absence of dystrophin protein. AOs have been shown to restore the expression of functional dystrophin via splice correction by intramuscular and systemic delivery in animal models of DMD and in DMD patients via intramuscular administration. Major challenges in developing this splice correction therapy are to optimize AO chemistry and to develop more effective systemic AO delivery. Peptide nucleic acid (PNA) AOs are an alternative AO chemistry with favorable in vivo biochemical properties and splice correcting abilities. Here, we show long-term splice correction of the DMD gene in mdx mice following …
引用总数
2010201120122013201420152016201720182019202020212022202320243136613425747711